Reipet – Lifestyle
Author:
Sagimet Biosciences Inc.
Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock
April 27, 2026
Sagimet Biosciences Provides Strategic and Corporate Updates
April 27, 2026
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
April 20, 2026
Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 6, 2026
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
March 11, 2026